


In the claims:

1. (currently amended) An isolated compound represented by A:



wherein

X represents independently for each occurrence O [,] or S [, or NR];

R represents independently for each occurrence H [, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, formyl, acyl, silyl, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$];

R^1 represents independently for each occurrence H [, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxy, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$];

R^2 represents independently for each occurrence H [, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, or $-(CH_2)_m-R_{80}$];

R^3 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, [[aryl, heteroaryl,]] or arylalkyl [, or $-(CH_2)_m-R_{80}$];

R^4 is absent or present between one and four times inclusive;

R^4 , if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;


R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.

2. (currently amended) An isolated compound represented by B:



wherein

X represents independently for each occurrence O [,] or S [, or NR];

R represents independently for each occurrence H [, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, formyl, acyl, silyl, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$];

R^1 represents independently for each occurrence H [, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino,

alkylamino, arylamino, arylakylamino, sulfhydryl, alkylthio, arylthio, arylakylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$];

R^2 represents independently for each occurrence H [, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, or $-(CH_2)_m-R_{80}$];

R^3 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, [[aryl, heteroaryl,]] or arylalkyl [, or $-(CH_2)_m-R_{80}$];

R^4 is absent or present between one and four times inclusive;

R^4 , if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylakylamino, sulfhydryl, alkylthio, arylthio, arylakylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;

R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.


3. (original) The compound of claim 1 or 2, wherein X represents O.
4. (canceled)
5. (canceled)
6. (canceled)
7. (original) The compound of claim 1 or 2, wherein R^3 represents alkyl.
8. (original) The compound of claim 1 or 2, wherein R^4 is absent.

9. (canceled)
10. (canceled)
11. (canceled)
12. (currently amended) The compound of claim 1 or 2, wherein X represents O; [[R represents H; R¹ represents H; R² represents H;]] and R³ represents alkyl.
13. (currently amended) The compound of claim 1 or 2, wherein X represents O; [[R represents H; R¹ represents H; R² represents H;]] R³ represents alkyl; and R⁴ is absent.
14. (currently amended) The compound of claim 1 or 2, wherein X represents O; [[R represents H; R¹ represents H; R² represents H;]] R³ represents ethyl; and R⁴ is absent.
15. (original) A formulation, comprising a compound of claim 1 or 2; and a pharmaceutically acceptable excipient.
16. (previously presented) A formulation, comprising a compound of claim 1 or 2; and a compound selected from the group consisting of analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxiolytics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastrointestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, antinarcotic, and anorectics.
17. (original) A formulation, comprising a compound of claim 1 or 2; and a compound selected from the group consisting of aceclofenac, acetaminophen, adomoxetine, almotriptan, alprazolam, amantadine, amcinonide, aminocyclopropane, amitriptyline, amolodipine, amoxapine, amphetamine, aripiprazole, aspirin, atomoxetine, azasetron, azatadine, beclomethasone, benactyzine, benoxaprofen, bismopropfen, betamethasone, bicifadine, bromocriptine, budesonide, buprenorphine, bupropion, buspirone, butorphanol, butriptyline, caffeine, carbamazepine, carbidopa, carisoprodol, celecoxib, chlordiazepoxide, chlorpromazine, choline salicylate, citalopram, clomipramine, clonazepam, clonidine, clonitazene, clorazepate, clonazepam, clobazepam, clonazepam, codeine, corticosterone, cortisone, cyclobenzaprine, cyproheptadine, demexiptiline, desipramine, desomorphine, dexamethasone, dexanabinol, dextroamphetamine sulfate,

dextromoramide, dextropropoxyphene, dezocine, diazepam, dibenzepin, diclofenac sodium, diflunisal, dihydrocodeine, dihydroergotamine, dihydromorphine, dimetacrine, divalproxex, dizatriptan, dolasetron, donepezil, dothiepin, doxepin, duloxetine, ergotamine, escitalopram, estazolam, ethosuximide, etodolac, femoxetine, fenamates, fenoprofen, fentanyl, fludiazepam, fluoxetine, fluphenazine, flurazepam, flurbiprofen, flutazolam, fluvoxamine, frovatriptan, gabapentin, galantamine, gepirone, ginko bilboa, granisetron, haloperidol, huperzine A, hydrocodone, hydrocortisone, hydromorphone, hydroxyzine, ibuprofen, imipramine, indiplon, indomethacin, indoprofen, iprindole, ipsapirone, ketaserin, ketoprofen, ketorolac, lesopitron, levodopa, lipase, lofepramine, lorazepam, loxapine, maprotiline, mazindol, mefenamic acid, melatonin, melitracen, memantine, meperidine, meprobamate, mesalamine, metapramine, metaxalone, methadone, methadone, methamphetamine, methocarbamol, methyl dopa, methylphenidate, methylsalicylate, methysergid(e), metoclopramide, mianserin, mifepristone, milnacipran, minaprine, mirtazapine, moclobemide, modafinil, molindone, morphine, morphine hydrochloride, nabumetone, nadolol, naproxen, naratriptan, nefazodone, neurontin, nomifensine, nortriptyline, olanzapine, olsalazine, ondansetron, opipramol, orphenadrine, oxaflozane, oxaprazin, oxazepam, oxitriptan, oxycodone, oxymorphone, pancrelipase, parecoxib, paroxetine, pemoline, pentazocine, pepsin, perphenazine, phenacetin, phendimetrazine, phenmetrazine, phenylbutazone, phenytoin, phosphatidylserine, pimoziide, pirlindole, piroxicam, pizotifen, pizotyline, pramipexole, prednisolone, prednisone, pregabalin, propanolol, propizepine, propoxyphene, protriptyline, quazepam, quinupramine, reboxitine, reserpine, risperidone, ritanserin, rivastigmine, rizatriptan, rofecoxib, ropinirole, rotigotine, salsalate, sertraline, sibutramine, sildenafil, sulfasalazine, sulindac, sumatriptan, tacrine, temazepam, tetrabenazine, thiazides, thioridazine, thiothixene, tiapride, tiasipirone, tizanidine, tofenacin, tolmetin, toloxatone, topiramate, tramadol, trazodone, triazolam, trifluoperazine, trimethobenzamide, trimipramine, tropisetron, valdecoxib, valproic acid, venlafaxine, viloxazine, vitamin E, zimeldine, ziprasidone, zolmitriptan, zolpidem, and zopiclone.

18. (currently amended) A method of treating a mammal suffering from depression, comprising the step of:

administering to said mammal a therapeutically effective amount of [[a compound of claim 1 or 2]] an isolated compound represented by A:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxy, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or -(CH₂)_m-R₈₀;


R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof; or

an isolated compound represented by B:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;


R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or -(CH₂)_m-R₈₀;

R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and
the compound is a single enantiomer; or
a pharmaceutically acceptable salt or prodrug thereof.

19. (currently amended) A method of treating a mammal suffering from fibromyalgia syndrome, comprising the step of:

administering to said mammal a therapeutically effective amount of [[a compound of claim 1 or 2]] an isolated compound represented by A:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl,

(arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;


R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof; or

an isolated compound represented by B:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R^1 represents independently for each occurrence H;

R^2 represents independently for each occurrence H;

R^3 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R^4 is absent or present between one and four times inclusive;

R^4 , if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxy, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy,

(alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;

R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;


m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.

20. (currently amended) A method of treating a mammal suffering from mental disorders including Functional Somatic Disorders, for example, depression, fibromyalgia syndrome, chronic fatigue syndrome, pain, attention deficit/hyperactivity disorder, and visceral pain syndromes (VPS), such as irritable bowel syndrome (IBS), noncardiac chest pain (NCCP), functional dyspepsia, interstitial cystitis, essential vulvodynia, urethral syndrome, orchialgia, and affective disorders, including depressive disorders (major depressive disorder, dysthymia, atypical depression) and anxiety disorders (generalized anxiety disorder, phobias, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder), premenstrual dysphoric disorder, temporomandibular disorder, atypical face pain, migraine headache, and tension headache, comprising the step of:

administering to said mammal a therapeutically effective amount of [[a compound of claim 1 or 2]] an isolated compound represented by A:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or -(CH₂)_m-R₈₀;


R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof; or

an isolated compound represented by B:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxy, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulphydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or -(CH₂)_m-R₈₀;

R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;


m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.

21. (original) The method of claim 18, 19, or 20, wherein said mammal is a primate, equine, canine or feline.
22. (original) The method of claim 18, 19, or 20, wherein said mammal is a human.
23. (original) The method of claim 18, 19, or 20, wherein said compound is administered orally.
24. (original) The method of claim 18, 19, or 20, wherein said compound is administered intravenously.

25. (original) The method of claim 18, 19, or 20, wherein said compound is administered sublingually.
26. (original) The method of claim 18, 19, or 20, wherein said compound is administered ocularly.
27. (original) The method of claim 18, 19, or 20, wherein said compound is administered transdermally.
28. (original) The method of claim 18, 19, or 20, wherein said compound is administered rectally.
29. (original) The method of claim 18, 19, or 20, wherein said compound is administered vaginally.
30. (original) The method of claim 18, 19, or 20, wherein said compound is administered topically.
31. (original) The method of claim 18, 19, or 20, wherein said compound is administered intramuscularly.
32. (original) The method of claim 18, 19, or 20, wherein said compound is administered subcutaneously.
33. (original) The method of claim 18, 19, or 20, wherein said compound is administered buccally.
34. (original) The method of claim 18, 19, or 20, wherein said compound is administered nasally.
35. (currently amended) A composition comprising a selective serotonin reuptake inhibitor and [[a compound of claim 1 or 2]] an isolated compound represented by A:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or -(CH₂)_m-R₈₀;


R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof; or

an isolated compound represented by B:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or-(CH₂)_m-R₈₀;


R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.

36. (currently amended) A composition comprising a selective norepinephrine reuptake inhibitor and [[a compound of claim 1 or 2]] an isolated compound represented by A:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;


R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxy, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or -(CH₂)_m-R₈₀;

R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and
the compound is a single enantiomer; or
a pharmaceutically acceptable salt or prodrug thereof; or
an isolated compound represented by B:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or-(CH₂)_m-R₈₀;


R₈₀ represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.

37. (currently amended) A composition comprising a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, and [[a compound of claim 1 or 2]] an isolated compound represented by A:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R¹ represents independently for each occurrence H;

R² represents independently for each occurrence H;

R³ represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R⁴ is absent or present between one and four times inclusive;

R⁴, if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxy, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy,

(alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;


R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof; or

an isolated compound represented by B:



wherein

X represents independently for each occurrence O or S;

R represents independently for each occurrence H;

R^1 represents independently for each occurrence H;

R^2 represents independently for each occurrence H;

R^3 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, or arylalkyl;

R^4 is absent or present between one and four times inclusive;

R^4 , if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio,

arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;


R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and


the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.


38. (currently amended) The composition of claim[[s]] 36 or 37, wherein said selective norepinephrine reuptake inhibitor is milnacipran.
39. (currently amended) The composition of any one of claims 35-37, wherein said isolated compound [[of claim 1 or 2 is CS1713]] is the hydrochloride salt of




40. (currently amended) The composition of any one of claims 35-37, wherein said isolated compound [[of claim 1 or 2 is CS1714]] is the hydrochloride salt of



41. (currently amended) The composition of any one of claims 35-37 [[40]], wherein said composition further comprises [[CS1814]] the hydrochloride salt of




42. (currently amended) A composition comprising a selective serotonin reuptake inhibitor




and [[CS1814]] the hydrochloride salt of

43. (currently amended) A composition comprising a selective norepinephrine reuptake inhibitor and [[CS1814]] the hydrochloride salt of



44. (currently amended) A composition comprising a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, and [[CS1814]] the hydrochloride



Response

Claims 1-3, 7, 8, and 12-44 are pending. Claims 4-6 and 9-11 have been canceled. Claims 1, 2, 12-14, 18-20, 35-44 have been amended. The claim amendments have been made to reflect the agreement reached between the Examiner and the Applicants' attorney during telephonic negotiations on Friday, August 27, 2005 and Thursday, September 8, 2005. The claim cancellations have been made because certain claims were rendered redundant by the claim amendments. No new matter has been added. For example, the hydrochloride salts previously referred to as CS1713, CS1714, and CS1814 are depicted *inter alia* in Figures 19, 22, and 30, respectively.

Request for One-Month Extension

Pursuant to 37 CFR 1.136(a), Applicants hereby request a one-month extension of time for filing a response to the final Office Action, mailed May 16, 2005, in the above-identified application. The Commissioner is hereby authorized to charge \$60.00, the appropriate amount for a Small Entity, to Deposit Account, No. 06-1448; Reference CPX-003.01. Further, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment of fees to our Deposit Account, No. 06-1448; Reference CPX-003.01.

Conclusion

In view of the above amendments and remarks, it is believed that the pending claims are in condition for allowance. The Applicants respectfully request reconsideration and withdrawal of the pending rejections. The Applicants thank the Examiner for careful consideration of the present case. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to contact the undersigned.

Patent Group
FOLEY HOAG LLP
155 Seaport Boulevard
Boston, MA 02210

(617) 832-1000
(617) 832-7000 (FAX)

Date: September 8, 2005

Respectfully submitted,
FOLEY HOAG LLP



Dana M. Gordon, Ph.D.
Registration No. 44,719
Attorney for Applicants